Ticker: ALC

UBS has downgraded Galderma Group AG (SIX: GALD) from "buy" to "neutral," citing valuation concerns and a cooling aesthetics market. The 12-month price target is revised to CHF120. Traders should brace for potential slowing growth in key product segments.

Alcon (SIX: ALCC) shares fell 2.9% post-Q2 earnings miss, despite a reaffirmed 2024 optimistic outlook. While segments like Surgical and Implantables showed growth, declines in Equipment and Ocular Health raise concerns. Analysts suggest potential margin improvements ahead.

Explore 3 healthcare stocks worth watching in September, with net profit margins over 10%, YTD gains up to 65%, and strong EBITDA margins.